An Evaluation of the Effect of the Erchonia® Zerona 6 Headed Scanner (EZ6) Six-week Treatment Protocol on Circumference Reduction of the Waist, Hips, Thighs and Upper Abdomen Clinical Study Protocol
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 4
- 主要终点
- Change in Combined Circumference Measurements
研究概览
简要总结
The purpose of this study is to determine whether low level laser light therapy is effective in reducing circumference of the waist, hips, thighs and upper abdomen over a 6 week period.
详细描述
The American Society of Plastic Surgeons (ASPS) 2011 report states that the market for cosmetic procedures has shown significant growth over the past two years, with 13.8 million cosmetic plastic surgery procedures performed in the United States in 2011, up 5% since 2010. While surgical cosmetic procedures significantly increased from 2010 to 2011, the overall growth in cosmetic procedures is primarily driven by a substantial rise in minimally-invasive procedures, that increased 6%, with nearly 12.2 million cosmetic minimally-invasive procedures having been performed in 2011. This highlights the growing consumer demand for non- or minimally-invasive cosmetic procedures that do not involve surgical procedures such as liposuction and the associated risks, potential complications and lengthy and painful recovery processes.
Low level laser light therapy offers a simple, non-invasive, safe, effective and side-effect free alternative to achieving body circumference reduction.
Justification for the assertion of anticipated safety and effectiveness of application of the Erchonia® EZ6 Laser low level laser therapy for the reduction of body circumference is found through three Food and Drug Administration (FDA) clearances for Erchonia® Low Level Laser devices for body circumference reduction indications, as follows:
K123237 (532 nanometer (nm) green light diodes): Erchonia® Zerona™ 2.0 Laser: is indicated for use as a non-invasive dermatological aesthetic treatment as an adjunct for individuals intending to undergo liposuction procedures for the reduction of circumference of hips, waist, and thighs.
K121695 & K082609 (635 nm red light diodes): Erchonia® ML Scanner (MLS) & Erchonia® Zerona: is indicated for use as a non-invasive dermatological aesthetic treatment as an adjunct for individuals intending to undergo liposuction procedures for the reduction of circumference of hips, waist, and thighs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body Mass Index (BMI) between 25 kg/m² and 40 kg/m²
- •Subject indicated for liposuction or use of liposuction techniques for the removal of localized deposits of adipose tissues that do not respond to diet and exercise for the hips, waist, thighs and upper abdomen. (As per the American Academy of Cosmetic Surgery's 2006 Guidelines for Liposuction Surgery developed by A joint Ad Hoc Committee of the American Society of Lipo-Suction Surgery (ASLSS) and the American Academy of Cosmetic Surgery (AACS))
- •Willing and able to abstain from treatments other than the study procedure for body contouring/circumference reduction/weight loss during study participation
- •Willing and able to maintain typical diet and exercise regimen during study participation
排除标准
- •Body Mass Index (BMI) less than 25 kg/m² or greater than 40 kg/m²
- •Known cardiovascular disease
- •Cardiac surgeries such as bypass, heart transplant surgery, pacemakers
- •Prior surgical intervention for body sculpting/weight loss
- •Medical, physical, or other contraindications for body sculpting/weight loss
- •Current use of medication known to affect weight levels/cause bloating or swelling and for which abstinence during study participation is not possible
- •Any medical condition known to affect weight levels and/or cause bloating or swelling.
- •Diagnosis of, and/or taking medication for, irritable bowel syndrome.
- •Active infection, wound or other external trauma to the study treatment areas
- •Known photosensitivity disorder
- •Active cancer or currently receiving treatment for cancer
- •Pregnant or planning pregnancy prior to study participation end
- •Serious mental health illness such as dementia/schizophrenia; psychiatric hospitalization in past two years.
- •Developmental disability or cognitive impairment that may preclude adequate comprehension of the consent form and/or ability to record the study measures
- •Involvement in litigation/worker's compensation/disability benefits related to the study parameters
- •Participation in clinical research in the past 30 days
结局指标
主要结局
Change in Combined Circumference Measurements
时间窗: Baseline and 6 weeks
Combined circumference measurement is calculated as the sum of the measurements for the individual body areas of the right and left thighs, hips, waist and upper abdomen. Change in combined circumference measurements is calculated as the difference in measurements from baseline to after completion of the 6-week procedure administration period. A negative (-) change indicates a reduction in combined circumference measurement across the evaluation period and is positive for study success. A positive (+) change indicates an increase in combined circumference measurements across the evaluation period and is negative for study success. A mean change for the study subject group of -3.0 inches or more in combined circumference measurements will be considered a clinically meaningful and statistically significant positive change indicative of study success.
次要结局
- Change in Body Weight(Baseline and 6 weeks)
- Change in Body Mass Index (BMI)(Baseline and 6 weeks)
- Subject Satisfaction With Study Outcome Rating(6 weeks)